News Sentiment

INSM sentiment intelligence

Insmed Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 60 Balanced news tone 60 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 108.32 Week of 17 Jul 2026
Weighted tone 60/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

80/100 classification confidence.

Company focus 51

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

-6.3% over one week, +13.1% over four weeks, trend inactive, and materially above fair value.

Latest direct headline Positive

Positive 12‑Month TPIP PAH Data Could Be A Game Changer For Insmed (INSM)

Market Reaction

Price moving ahead of tone

70/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 80/100 classification
One-week reaction -6.3% Price reacting lower
Trend fit Trend inactive 13.1% over four weeks
Fair value 28.1% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 27
Neutral 29
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 51
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 14
simplywall.st 7
Insmed Incorporated Investor Relations 5
Investing.com 4
Stock Titan 4
Moomoo 3
TradingView 3
PR Newswire 2

Event Lens

What the news is about

Classified themes
Market update 34
Earnings 17
Analyst action 7
Guidance 1
Regulatory and legal 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 60
Cantech Letter Direct company coverage

Buy Insmed for a double, this analyst says

Roth Capital Partners analyst Adam Walsh reiterated his "Buy" rating and $212.00 target on Insmed after the company released positive 12-month data from its TPIP extension study. The data showed durable improvement in six-minute walk distance for patients with pulmonary arterial

Tone
Positive 91/100
Event
Analyst action
Published
20 Jul 2026 15:39
Source
Cantech Letter
Investing.com Direct company coverage

Insmed stock price target maintained at $220 by H.C. Wainwright

H.C. Wainwright has reiterated a Buy rating and a $220 price target for Insmed (NASDAQ:INSM) following positive 12-month open-label extension data for its TPIP drug, indicating consistent efficacy and no new tolerability concerns. While this data de-risks the investment, the firm

Tone
Positive 81/100
Event
Analyst action
Published
20 Jul 2026 11:39
Source
Investing.com
Simply Wall Street Direct company coverage

Is Insmed (INSM) Undervalued After Positive TPIP Data Backed A Phase 3 Push?

Insmed (INSM) shares are in focus following positive 12-month data from an open-label extension study for treprostinil palmitil inhalation powder in pulmonary arterial hypertension. Despite recent share price volatility, analysts suggest Insmed is significantly undervalued, with

Tone
Positive 62/100
Event
Market update
Published
20 Jul 2026 02:11
Source
Simply Wall Street
Webull Direct company coverage

Insmed (INSM) Reports 12 Month TPIP Data That Sets Up Phase 3

Insmed has reported positive 12-month open-label extension data for TPIP in pulmonary arterial hypertension, showing sustained improvements in clinical endpoints with no new safety signals. These results pave the way for a Phase 3 randomized, controlled trial, providing a new dat

Tone
Positive 66/100
Event
Earnings
Published
19 Jul 2026 08:11
Source
Webull
Moomoo Direct company coverage

A Quick Look at Today's Ratings for Insmed(INSM.US), With a Forecast Between $161 to $237

This article provides an overview of recent analyst ratings for Insmed (INSM.US), highlighting a consensus price target range of $161 to $237. It outlines the bullish sentiment surrounding the stock based on these expert evaluations. The information suggests a positive outlook fo

Tone
Positive 77/100
Event
Guidance
Published
17 Jul 2026 15:39
Source
Moomoo
Investing.com Direct company coverage

Insmed stock price target maintained at $200 by Stifel on trial data

Stifel reiterated a Buy rating and a $200 price target for Insmed (NASDAQ:INSM) after the company released 12-month open-label extension data from its Phase 2b trial for TPIP, a pulmonary arterial hypertension treatment candidate. The data showed continued clinical benefit and re

Tone
Positive 76/100
Event
Analyst action
Published
17 Jul 2026 12:10
Source
Investing.com
BioSpace Direct company coverage

Insmed moves closer to $6B opportunity as PAH drug shows long-term durability

Insmed's investigational pulmonary arterial hypertension (PAH) drug, treprostinil palmitil inhalation powder (TPIP), demonstrated "impressive" long-term efficacy and biomarker improvements in an open-label extension study. Guggenheim Partners projects peak TPIP sales to exceed $6

Tone
Positive 73/100
Event
Regulatory and legal
Published
17 Jul 2026 12:10
Source
BioSpace
Moomoo Direct company coverage

Insmed Says Treprostinil Shows Sustained Benefit to Pulmonary Arterial Hypertension Patients

Insmed announced that data from their Phase 1 TREMOLOTM and Phase 2 BEATTM studies indicate that treprostinil showed sustained benefits for pulmonary arterial hypertension (PAH) patients. The data suggests that the drug could improve pulmonary vascular hemodynamics, functional ca

Tone
Positive 70/100
Event
Market update
Published
17 Jul 2026 08:11
Source
Moomoo
BioSpectrum Asia Direct company coverage

Insmed reports 12-month TPIP data in pulmonary arterial hypertension

Insmed has released positive 12-month data from an ongoing open-label extension study of treprostinil palmitil inhalation powder (TPIP) for pulmonary arterial hypertension (PAH). The data showed sustained improvements in functional, biomarker, and risk-status measures in PAH pati

Tone
Positive 80/100
Event
Market update
Published
17 Jul 2026 08:10
Source
BioSpectrum Asia
Seeking Alpha Direct company coverage

Insmed Incorporated (INSM) Discusses 12-Month Results From Ongoing TPIP Open-Label Extension Study in PAH Patients - Slideshow (NASDAQ:INSM)

Insmed Incorporated (INSM) has released a slide deck detailing the 12-month results from its ongoing open-label extension study of TPIP in patients with Pulmonary Arterial Hypertension (PAH). This information was published in conjunction with an event. The study's findings are pr

Tone
Positive 71/100
Event
Earnings
Published
16 Jul 2026 20:27
Source
Seeking Alpha
Insmed Incorporated Investor Relations Direct company coverage

Insmed Announces Positive 12-Month Data from the Ongoing Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Patients with Pulmonary Arterial Hypertension

Insmed announced positive 12-month data from its open-label extension study of treprostinil palmitil inhalation powder (TPIP) for pulmonary arterial hypertension (PAH). The data showed sustained improvement in efficacy measures, including a reduction in mortality risk, and TPIP w

Tone
Positive 73/100
Event
Market update
Published
16 Jul 2026 19:10
Source
Insmed Incorporated Investor Relations
Investing.com Direct company coverage

Insmed reports 12-month data for PAH treatment candidate

Insmed (NASDAQ:INSM) announced positive 12-month open-label extension study data for its treprostinil palmitil inhalation powder (TPIP) in patients with pulmonary arterial hypertension (PAH). Patients showed significant improvement in six-minute walk distance and decreased NT-pro

Tone
Positive 72/100
Event
Market update
Published
16 Jul 2026 11:42
Source
Investing.com
TradingView Direct company coverage

Insmed reports positive 12-month OLE results for TPIP showing sustained 6MWD, ~60% NT-proBNP drop

Insmed announced positive 12-month Open-Label Extension (OLE) results for TPIP, demonstrating sustained efficacy and good tolerability. The study showed a mean 6MWD improvement in both continued and placebo-crossed groups, aligning by Month 12, along with a significant ~60% drop

Tone
Positive 72/100
Event
Earnings
Published
16 Jul 2026 10:42
Source
TradingView
https://hrtoday.in/ Direct company coverage

William Haggerty Joins Insmed Incorporated as Senior Director of People Operations

Insmed Incorporated has appointed William Haggerty as Senior Director of People Operations. With over two decades of experience in HR transformation, talent strategy, and AI-enabled workforce innovation, Haggerty previously served at IBM where he spearheaded AI-powered talent ini

Tone
Positive 72/100
Event
Market update
Published
14 Jul 2026 17:35
Source
https://hrtoday.in/
Sahm Direct company coverage

Insmed (INSM) After Insider Selling And Brensocatib Hopes What Does Valuation Say

Insmed (INSM) is under scrutiny after its Chair and CEO sold shares following the exercise of stock options. Despite a year-to-date share price drop, longer-term holders have seen significant gains. The article explores Insmed's valuation, highlighting a narrative suggesting it's

Tone
Neutral 50/100
Event
Market update
Published
13 Jul 2026 18:39
Source
Sahm
TradingView Direct company coverage

Enterprise value to EBIT forward of Insmed Incorporated – BMV:INSM

This article provides financial data for Insmed Incorporated (BMV:INSM), focusing on its enterprise value to EBIT forward. It displays the company's financial overview on TradingView, indicating that the market was closed at the time of publication with no trades. The content pri

Tone
Neutral 50/100
Event
Market update
Published
12 Jul 2026 08:41
Source
TradingView
Investing.com South Africa Direct company coverage

Form 4 Insmed Inc For: 10 July By Investing.com

This article from Investing.com reports on a Form 4 filing for Insmed Inc. The filing was made on July 10, 2026. The article primarily consists of financial market data and navigation, with the core content being the brief announcement of the Form 4.

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 21:09
Source
Investing.com South Africa
Investing.com Nigeria Direct company coverage

Insmed CEO William Lewis sells over $1.25m in company stock

Insmed CEO William Lewis sold 10,699 shares of the company's common stock for over $1.25 million on July 9, 2026, while concurrently acquiring the same number of shares through stock option exercises. These transactions were executed under a Rule 10b5-1 trading plan. The company'

Tone
Negative 40/100
Event
Market update
Published
10 Jul 2026 21:09
Source
Investing.com Nigeria
Moomoo Direct company coverage

Insmed Insider Sold Shares Worth $1,256,084, According to a Recent SEC Filing

Insmed insider Paul C. Chapman sold 37,294 shares of the company's common stock on June 27, 2024, at an average price of $33.68 per share, totaling $1,256,084. Following this transaction, Chapman directly owns 82,234 shares of Insmed. This sale comes as the company continues to d

Tone
Negative 39/100
Event
Market update
Published
10 Jul 2026 21:09
Source
Moomoo
Stock Titan Direct company coverage

INSMED Inc (NASDAQ: INSM) CEO executes 10b5-1 option exercise and sale of 10,699 shares

INSMED Inc CEO William Lewis exercised stock options for 10,699 shares and subsequently sold the same number of shares on July 9, 2026, through open-market transactions. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted in September 2025. Lewi

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 20:09
Source
Stock Titan
Quiver Quantitative Direct company coverage

Insmed Slides 4% as Investors Weigh Insider Filing and Near-Term Catalyst Gap

Insmed's stock (INSM) dropped 4% following an insider ownership filing and general biotech volatility, as there was no major new operating or clinical update. The filing by Chief Medical Officer Martina Flammer is seen as a potential factor causing de-risking by investors, who ar

Tone
Negative 36/100
Event
Market update
Published
10 Jul 2026 17:37
Source
Quiver Quantitative